|

Brain Effects of Gamma Frequency Sensory Stimulation (40Hz Light, Sound and Other Devices)

RECRUITINGPhase 2Sponsored by Massachusetts Institute of Technology
Actively Recruiting
PhasePhase 2
SponsorMassachusetts Institute of Technology
Started2018-02-20
Est. completion2027-01-30
Eligibility
Age18 Years – 100 Years
Healthy vol.Accepted
Locations1 site

Summary

Despite the huge healthcare and economic impact of AD, there is still no disease modifying therapeutics available. In fact, the available therapeutics show low efficacy at best in the treatment of cognitive impairment in dementia. Development of a non-invasive medical device that is effective in slowing cognitive impairment is not only revolutionary but also possibly cost- effective. In this study, participants will come to MIT for a 1-day visit and the investigators will evaluate the effects of GENUS in cognitively normal, healthy adults. Investigators will use Electroencephalogram (EEG), Magnetoencephalography (MEG), magnetic resonance imaging (MRI), neuropsychological testing, and blood sampling in subsets of participants to evaluate for biological effects and safety of GENUS stimulation.

Eligibility

Age: 18 Years – 100 YearsHealthy volunteers accepted
Inclusion Criteria:

* Have adequate visual and auditory acuity for visual and auditory stimulation to allow for neuropsychological testing.
* Be able to comply with neuropsychological testing and other study procedures in opinion of site PI.

Exclusion Criteria: Participants will be screened for the following exclusion criteria including if they

* History of seizure or medical diagnosis of epilepsy.
* Have MRI contraindications, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body.
* Under the discretion of the site investigator, the site investigator feels the subject cannot complete sufficient key study procedures. Exceptions to these guidelines may be considered on a case-by-case basis at the discretion of the Project Director.

Conditions3

Alzheimer DiseaseAlzheimer's DiseaseCognitively Healthy People

Locations1 site

MIT
Cambridge, Massachusetts, 02139
Ana Trisini Lipsanopoulos, BS617-258-7723anat13@mit.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.